Purpose Healing Center Establishes Ground Breaking Treatment Services in Scottsdale, Arizona

Press Release – updated: Jan 24, 2020 15:00 MST

SCOTTSDALE, Ariz., January 24, 2020 ( – Purpose Healing Center is an accredited treatment facility providing inpatient, residential and outpatient evidence-based and comprehensive treatment programs for drug and alcohol addiction. Headquartered in Scottsdale, Purpose Healing Center offers individualized treatment plans with a focus on dual diagnosis and co-occurring disorders.
Alcohol and drug addiction is a prevailing problem in the US and affects millions of families. According to SAMHSA or The Substance Abuse and Mental Health Services Administration, about 22.5 million Americans over the age of 12 needed treatment for drugs and alcohol in 2014 alone. Substance abuse has a detrimental effect not just on the mental but also on the physical health of individuals. In fact, patients affected by the addiction are more likely to develop heart disease and diabetes.
The National Institute of Health also reported that Alcohol Use Disorder (AUD) or chronic alcoholism, is characterized by an inability to control or stop alcohol use despite its destructive consequences, is also a major problem in the US. About 15.2 million adults and youth are affected by AUD. Moreover, the World Health Organization reported that alcohol contributes to over 200 diseases.
With this in mind, the Purpose Healing Center compiles all the latest research on alcohol and drug addiction to provide groundbreaking treatment to individuals and families affected by it. They aim to provide only the best and effective recovery programs that will defeat this addiction.
About Purpose Healing Center
Purpose Healing Center is a drug and alcohol rehab facility in Scottsdale and Phoenix, Arizona. They serve patients in Mesa, Chandler, Phoenix, Avondale, Gilbert and Scottsdale residents. Their main objective is to provide unprecedented treatment services to end the cycle of drug and alcohol addiction. They also accept most insurance providers including Aetna, Humana, Cigna, UnitedHealthcare, BlueCross BlueShield and AmeriHealth Caritas.
More information about Addiction Recovery Center is found on their website
Contact:Phone: 480-579-3319Email:
9332 N 95th Way suite b-203Scottsdale, AZ 85258
Source: Purpose Healing Center

Catalent Biologics Supports DiaMedica’s New Treatment for Chronic Kidney Disease

GPEx technology has been shown to be particularly suited to the development of a high-expressing cell line for this difficult-to-express protein, compared to other approaches that DiaMedica had tried previously.

SOMERSET, N.J. (PRWEB) January 23, 2020
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today welcomed the news that DiaMedica Therapeutics has received U.S. Food and Drug Administration (FDA) approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease (CKD). On behalf of DiaMedica, Catalent has produced a cGMP batch of the drug at its Madison, Wisconsin facility to support the trial using its proprietary GPEx® cell line development technology. DiaMedica intends to initiate participant enrollment in the clinical study in the next few weeks.
Catalent’s proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. The advantages of applying GPEx technology span from early feasibility studies to clinical manufacturing, through to commercial-scale production. Twelve biopharmaceutical drugs have been approved using Catalent Biologics’ GPEx technology, with more than 120 additional therapeutic candidates in ongoing clinical trials. In addition to Madison, the Catalent Biologics network also includes a second drug substance development and manufacturing site in Bloomington, Indiana. Both state-of-the-art facilities can provide clinical and commercial manufacturing for GPEx and non-GPEx cell lines. The Bloomington facility and the company’s European sites in Brussels, Belgium and Anagni, Italy also provide clinical and commercial drug product manufacturing for biologics.
“GPEx technology has been shown to be particularly suited to the development of a high-expressing cell line for this difficult-to-express protein, compared to other approaches that DiaMedica had tried previously,” commented Michael Riley, Region President, Biologics North America. “We look forward to working with DiaMedica on this exciting and important candidate, as well as potentially others in DiaMedica’s future development pipeline.”
In addition to the proven GPEx platform, Catalent recently announced the launch of its next-generation cell line development technology, GPEx® Boost. GPEx Boost enhances the existing technology through multiple improvements, including utilization of a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line. The combination of technology and platform enhancements has resulted in improved ability of cells to produce high titers and increase specific productivities of a protein of interest.
GPEx Boost has been shown to improve titers up to four-fold, potentially to 10 g/L for standard monoclonal antibodies, while maintaining the stability benefits offered by the traditional GPEx platform. In addition, benefits have been observed in cell growth and viability. Developmental timelines for projects can be shortened and made more efficient by combining this new platform with the rapid screening capabilities of Berkeley Lights’ Beacon® optofluidic platform, and ambr® automated micro bioreactors. The first customer has already signed up to leverage the technology for a Fc-fusion protein.
For further information visit
About Catalent BiologicsFor more than two decades, Catalent Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and to date, 12 biopharmaceutical drugs produced using GPEx® cell line development technology have been approved and marketed, with more than 120 ongoing clinical trials utilizing therapeutic candidates developed using the GPEx® platform. A further 25 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Catalent’s latest addition, Paragon Gene Therapy, provides industry-leading capabilities and expertise in the development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines and oncolytic virus production. Its manufacturing facilities in Baltimore, Maryland have produced over 100 GMP batches across 40 clinical and commercial programs. Using advanced technology and tailored solutions for clinical through commercial supply, Catalent Biologics brings better biologic treatments to patients, faster.
About CatalentCatalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit
More products. Better treatments. Reliably supplied.™
About DiaMedica Therapeutics, Inc.DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

Share article on social media or email:

Dr Steven Shoshany Unveils Individualized Integrated Y-Strap Treatment  in NYC

While Dr. Shoshany has been a longtime provider of long axis traction, and spinal decompression, he recently decided to specifically add the Y-Strap adjustment as yet another tool in his vast array of treatments. He is aware of the online Y-Strap adjustment craze and wants to bring a more measured, practical approach to the technique, now so lauded for its newfound extreme status.(PRWeb January 20, 2020)Read the full story at

Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis

Press Release – updated: Jan 20, 2020 11:00 EST

PARAMUS, N.J., January 20, 2020 ( – Polaryx Therapeutics, a biotech company developing patient-friendly small molecule therapeutics for lysosomal storage disorders announced today that the Company has received an Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of LINCL patients with PLX-200.
Neuronal Ceroid Lipofuscinoses are a group of rare autosomal recessive neurodegenerative lysosomal storage disorders. Among them, LINCL is caused by mutations leading deficiency or loss of function of tripeptidyl peptidase 1 (TPP1). Intracellular accumulation of auto-fluorescent lipoproteins is one of the typical characteristics of LINCL resulting in deterioration of neurons in both the brain and other organs, such as the retina. Patients suffer from vision loss, severe seizures, and declining motor function, leading to premature death. Polaryx has advanced a unique repurposing drug development strategy to provide patients with a safe and effective oral treatment option.
“We are very excited about the IND approval from the FDA, as this will allow us to advance PLX-200 clinical studies for LINCL patients. We will prepare the clinical trial with PLX-200 as soon as possible,” says Dr. Hahn-Jun Lee, M.Sc., Ph.D., President and CEO of Polaryx Therapeutics, Inc.
Dr. Raymond Wang, M.D., Ph.D., the Foundation of Caring Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s Hospital in Orange, California, also stated that “CLN2 disease is a rare progressive and fatal neurodegenerative disorder affecting young children. There is a serious unmet need for non-invasive therapies targeted against CLN2 disease. I congratulate Polaryx Therapeutics for developing its PLX-200 candidate to target this devastating disease and for securing approval from the FDA to proceed with clinical studies to assess the safety, tolerability, and efficacy of PLX-200 for children with CLN2 disease.”
Polaryx Therapeutics, Inc
Polaryx Therapeutics, Inc is dedicated to developing drug candidates for lysosomal storage disorders, for which there is currently no safe and patient-friendly treatment option available. Lysosomal storage disorders are a group of rare inherited genetic disorders caused by the dysfunction of lysosomal enzymes and/or molecules important in the function of the enzymes. Young children are victims of these devastating diseases and die at an early age due to lack of treatment options. Polaryx is repurposing existing safe oral medications and/or developing new drugs, so that the treatment is patient-friendly for a prolonged use.
PLX-200 is a repurposed drug that binds to the retinoid X receptor-α (RXRα), which binds to PPARα thereby up-regulating the expression of TPP1 mRNA in brain cells via the PPARα/RXRα heterodimer. PLX-200 also activates PPARα, which enhances production of transcription factor EB (TFEB) in brain cells. TFEB then binds to the promoter of genes involved in lysosome biogenesis and activates their production. Thus, TFEB regulates lysosomes due to its effects on the expression of lysosomal genes. PLX-200 also has additional important activities, such as reducing inflammation and preventing cell death (apoptosis).
Late Infantile Neuronal Ceroid Lipofuscinosis
Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL or CLN2) is caused by deficiency and/or loss of TPP1 caused by mutations in the Cln2 gene. TPP1, a soluble 46 kDa acid protease found in the lysosome, removes tripeptides from the N-terminus of peptides. Cln2 gene mutations result in a deficiency and/or loss of function of the TPP1 enzyme, which leads to the intralysosomal accumulation of auto-fluorescent lipofuscin. Neurons and other cells of the body accumulate auto-fluorescent lipofuscin that is highly enriched in ATP synthase subunit C. This leads to seizures, regression in developmental milestones, ataxia, visual impairment, motor deterioration, dementia, and early death between the age of six and the early teenage years.
Media Contact
Hahn-Jun Lee, M.Sc.,
Source: Polaryx Therapeutics, Inc

International Research Collaboration Reveals Promising Drug Candidate for Treatment of Blood Cancers

Press Release – updated: Jan 16, 2020 09:00 EST

BUFFALO, N.Y. and SYDNEY, January 16, 2020 ( – An international research collaboration between the United States and Australia has revealed a promising new drug that could treat high-risk leukemia.
Today, OncoTartis, Inc. and Children’s Cancer Institute jointly announced the publication of two research manuscripts in a leading onco-hematological journal Leukemia, both devoted to the OncoTartis’ clinical drug candidate OT-82.
A significant proportion of blood cancers in both adults and children remain resistant to current treatments and are often fatal. The results of studies conducted collaboratively by teams in Buffalo and Sydney open a new treatment opportunity for patients with currently incurable blood cancers by introducing a new drug candidate shown to be highly effective in preclinical models.
The first paper ( describes the discovery, mechanism of action, toxicological profile and preclinical efficacy of OT-82 that was developed by OncoTartis for treatment of refractory leukemias and lymphomas. It takes advantage of the discovery of extremely high dependence of malignancies originating from the hematopoietic system on elevated levels of nicotinamide dinucleotide (NAD), an essential component of multiple metabolic and stress response mechanisms of the cell. OT-82 inhibits one of the major enzymes, nicotinamide phosphoribosyl transferase (NAMPT) responsible for NAD production. Its further clinical development is specifically focused on blood-derived cancers as the main disease target. OT-82 is currently undergoing a multicenter Phase I trial in the US (
The second paper on OT-82 ( describes a study conducted at Children’s Cancer Institute (Sydney). The Institute has been a world leader in establishing a large collection of refractory children’s leukemias grown in laboratory mice for new drug testing. These are widely accepted to be the most clinically-relevant models of childhood leukemia anywhere in the world.
This collection was utilized to compare the efficacy of OT-82 with current treatments for childhood leukemia. OT82 demonstrated remarkable efficacy when used alone and was even more effective when used in combination with conventional treatments, thereby indicating promise for children with high-risk blood cancers.
Currently, OT-82 is being tested in a clinical trial of adults with relapsed or refractory lymphoma. Following the successful completion of this trial, it is anticipated that the drug will proceed to clinical trial in children with high-risk acute lymphoblastic leukemia.
Professor Andrei Gudkov from Roswell Park Comprehensive Cancer Center in Buffalo NY, a Chief Scientific Officer of OncoTartis, said: “The main principle of the research strategy that led us to OT-82 was the identification of a pharmacological agent specifically toxic for malignant cells of blood origin. We were surprised when the compound that came out of an unbiased search appeared to be a NAMPT inhibitor, an enzyme that has been considered as a target for cancer treatment but whose association with malignancies of blood origin was unknown. We are especially excited about the potential use of OT-82 for treatment of refractory childhood malignancies, an opportunity revealed in the joint studies with our Australian partners.”
Professor Michelle Haber AM, Executive Director of Children’s Cancer Institute in Sydney, indicated this was a promising development for children with high-risk leukemia.
“For children with particularly aggressive leukemia, the options for effective yet safe treatments are extremely limited and therefore novel therapeutic options are urgently needed. If OT-82 is found to be safe and effective in adults, we are very hopeful that it may provide an exciting new treatment approach for the worst cases of pediatric leukemia, with the added potential benefit of allowing reductions in doses of chemotherapy and hence diminished adverse treatment side-effects for these children.”
Dr. Michelle Henderson, the Senior Scientist, who together with Dr. Klaartje Somers led the research at Children’s Cancer Institute, added: “In our hands, OT-82 has proven to be one of the more broadly active compounds tested so far in this panel of high-risk pediatric acute lymphoblastic leukemia.” Dr. Somers concluded: “OT-82 thus appears to be a promising anti-cancer drug for the treatment of a broad range of high-risk and aggressive pediatric acute lymphoblastic leukemia subtypes for which novel therapeutic options are urgently needed.”
The research at Children’s Cancer Institute was possible thanks to the support of the National Cancer Institute (part of the US National Institutes of Health), The National Health and Medical Research Council of Australia, Cancer Australia, The Kids’ Cancer Project, The Leukaemia Foundation, Anthony Rothe Memorial Trust, Cancer Council NSW, Tenix Foundation, ISG Foundation, the Children’s Leukemia & Cancer Research Foundation (Perth) and the Australian Government Department of Education and Training.
Contact: Aleksandra Kotlyarova, (415)
About OncoTartis: OncoTartis, Inc. ( is a private biotechnology company established in 2011. The Company’s founding IP came from the laboratory of Prof. Andrei Gudkov at the Roswell Park Cancer Institute (Buffalo, NY).
About Children’s Cancer Institute: Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision is to save the lives of all children with cancer and improve their long-term health, through research. The Institute has grown to now employ over 300 researchers, operational staff and students, and has established a national and international reputation for scientific excellence. Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments that can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimize side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life. More at
Source: OncoTartis, Inc.

Nurx Introduces Convenient & Stigma-Free Treatment for Herpes

In addition to offering online consultations and home delivery of medication, the health tech company accepts health insurance and offers transparent pricing(PRWeb January 14, 2020)Read the full story at